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Hemolytic uremic syndrome (HUS) is a disease of
microangiopathic hemolytic anemia, thrombocytope-
nia and acute renal failure. About 90% of cases are
secondary to infections by Escherichia coli strains
producingShiga-like toxins (STEC-HUS),while 10%are
associated with mutations in genes encoding proteins
of complement system (aHUS). We describe two
patients with a clinical history of STEC-HUS, who
developed end-stage renal disease (ESRD) soon after
disease onset. They received a kidney transplant but
lost the graft for HUS recurrence, a complication more
commonly observed in aHUS. Before planning a
second renal transplantation, the two patients under-
went genetic screening for aHUS-associated muta-
tions that revealed the presence of a heterozygous CFI
mutation in patient #1 and a heterozygous MCP
mutation in patient #2, and also in her mother who
donated the kidney. This finding argues that the two
cases originally diagnosed as STEC-HUS had indeed
aHUS triggered by STEC infection on a genetic
background of impaired complement regulation. Com-
plement gene sequencing should be performed before
kidney transplantation in patients who developed
ESRD following STEC-HUS since they may be undiag-
nosed cases of aHUS, at risk of posttransplant
recurrence. Furthermore, genetic analysis of donors
is mandatory before living-related transplantation to
exclude carriers of HUS-predisposing mutations.
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Introduction
Hemolytic uremic syndrome (HUS) is a rare disease
characterized by the triad of microangiopathic hemolytic
anemia, thrombocytopenia and acute renal failure, with a
worldwide incidence of 0.7–2 cases/year/100 000
people (1).
About 90% of patients develop typical diarrhea-associated
HUS, most commonly triggered by entero hemorrhagic
strains of E. coli, mainly of serotype O157:H7, producing
Shiga-like toxins (STEC) (2,3). STEC-HUS occurs primarily in
children (4). However, a large outbreak (>4000 cases) of
gastroenteritis and HUS, caused by an unusual enter-
oaggregative STEC strain (O104:H4) and predominantly
affecting adults, occurred in Germany in 2011 (5). More
than 25%of infected subjects developedHUS, a proportion
much higher than those recorded in outbreaks of enter-
ohemorrhagic STEC (5).
In STEC-associated HUS, binding of Shiga-like toxin (Stx) to
globotrialosyl ceramide receptors, highly expressed on
glomerular endothelial cells, generates a cascade of signals
resulting in expression of chemokines and adhesion
molecules, complement activation, leukocyte recruitment
and thrombus formation (3,4,6–8).
More than 90% of childhood cases of STEC-HUS fully
recover from acute disease, although long-term renal
sequelae have been reported in up to 25% of patients
(9). The reasons why only a small fraction of STEC-infected
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subjects develops a severe form of HUS is not clear, but a
role of genetic predisposition has been hypothesized (10).
On the other hand, 10%of HUS cases are not associated to
STEC infections (atypical HUS, aHUS). Mutations in genes
encoding for proteins of the complement system have
been shown to predispose to aHUS (1). The complement
system is involved in the immediate defense against
pathogens through three different pathways, the classical,
the lectin and the alternative pathways, converging at the
cleavage of C3. About 60% of patients with aHUS carry
mutations in genes encoding regulatory proteins of the
alternative pathway (AP) of complement, like factor H
(CFH), factor I (CFI) and membrane cofactor protein (MCP),
or gain-of-function mutations in the genes of the two
components of the AP C3 convertase, C3 and factor B
(CFB) (11). Genetic abnormalities of the endothelial
anticoagulant and complement-inhibitory protein thrombo-
modulin (THBD) have also been reported in aHUS (12). In
addition, anti-CFH autoantibodies have been described
mostly in children that lack CFHR1 and CFHR3 (CFH-related
proteins 1 and 3) due to a deletion of the corresponding
genes (13–16). All the above abnormalities result in
uncontrolled complement activation on endothelial cell
surface (11,17–19).
The clinical outcome of aHUS is usually unfavorable. About
50% of cases progress to end stage renal disease (ESRD)
and up to 25% may die during the acute phase (20).
Here we describe two patients with a clinical history of
STEC-HUS, selected among 41 STEC-HUS patients of the
International Registry of Hemolytic Uremic Syndrome/
Thrombotic Thrombocytopenic Purpura (HUS/TTP). Both
patients developed ESRD soon after disease onset and
received a kidney graft, one from a deceased donor and one
from a living-related donor. Disease recurrence is uncom-
mon in patients transplanted after STEC-HUS (20), and
indeed the other three STEC-HUS transplanted patients of
the Registry had an excellent graft outcome. At variance
both cases here presented lost the kidney graft for HUS
recurrence, a complication more commonly observed in
aHUS (19,20). Thus, before planning a second renal
transplantation, the patients underwent genetic screening
for aHUS-associated genes. We found a heterozygous
CFI mutation in patient #1 and a heterozygous MCP
mutation in patient #2 and also in her mother, who donated
the kidney.
We argue that the two cases originally diagnosed as STEC-
HUS had indeed aHUS triggered by STEC infection on a
genetic background of impaired complement regulation,
which predisposed to development of posttransplant aHUS
recurrence.
We discuss the implications of these findings for pretrans-
plant genetic counseling in patients who developed ESRD
following STEC-HUS.
Material and Methods
The two patients were selected among those with diagnosis of STEC-HUS
referred to the International Registry of HUS/TTP.
The patients and healthy controls provided informed written consent. The
study was approved by the Ethics Committee of the Azienda Sanitaria
Locale, Bergamo, Italy.
Genomic DNA was extracted from peripheral blood leukocytes (Nucleon
BACC2 kit, Amersham, UK). The coding sequences and the intronic flanking
regions of complement genes were screened by direct sequencing (AB-
3730 sequencer).
CFHR3-CFHR1 deletion was detected by Multiplex Ligation-dependent
Probe Amplification, MLPA (SALSA MLPA P236-A1 kit, MRC Holland).
Complement C3 and C4 levels in serum were evaluated by kinetic
nephelometry; CFH and CFI levels were measured by enzyme-linked
immunosorbent assay (ELISA).
Paraffin-embedded sections of kidney biopsy of patient #1 were analyzed
by light microscopy after staining with hematoxylin and eosin for
histopathological evaluation. Additional sections were analyzed for
deposition of C3 and C5b-9 using mAb anti-C3 (Quidel, San Diego, CA)
and mAb WU 13–15 anti-C9 neoantigen (a gift from Prof. R. Wurzner,
Insbruck, Austria) as primary antibodies and the streptavidin–biotin–
peroxidase complex system.
Patient #1
The clinical course of the patient, at present 47 years old, was partially
described in a previous report (21). She was first hospitalized at the age
of 26 years because of watery diarrhea, profuse vomiting and syncope.
Laboratory exams showed platelet count 27,000/mL, hemoglobin 8.1 gr/
dL, hematocrit 26%, LDH 2.200 U/L and serum creatinine 2 mg/dL. The
diagnosis of HUS was made. Search for E. coli infection showed positivity
for anti-Stx and anti-E. coli O157:H7 lipopolysaccharide antibodies in
serum. A renal biopsy demonstrated classic histological features of
thrombotic microangiopathy (Figure 1A–D). A diffuse and intense
reactivity for C3 and C9, the latter reflecting formation of the terminal
complement complex (C5b-9), was evident in glomeruli with overt
ischemic alterations (Figure 1E–F).
Biochemical analyses, performed during the acute phase, showed low
C3 levels (65.6 mg/dL; normal range: 90–180 mg/dL) and normal C4
levels (14.6 mg/dL; normal range: 10–40 mg/dL), suggesting activation of
the AP.
Despite intensive plasma exchange the disease progressed, renal function
deteriorated and hemodialysis was started. Seizures and hypertensive
encephalopathy developed and the patient underwent bilateral nephrectomy
that was followed by complete neurological and hematological remission. At
discharge, the patient was on chronic hemodialysis but her blood pressure
was well-controlled (21).
At 33 years of age the patient received a cadaveric renal allograft under
immunosuppressive therapy with cyclosporine, mycophenolate mofetil
and methylprednisolone; however, one year after transplantation she
developed clinical and laboratory signs of HUS recurrence (platelet count
37 000/mL, hemoglobin 9 gr/dL, hematocrit 29%), with severe renal and
neurological involvement (serum creatinine 4 mg/dL, seizures). No
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improvement was achieved with plasma exchange and infusion, the
patient developed ESRD and the graft was explanted. About 10 years
later, before planning a second kidney transplantation, the patient was
referred to our center to investigate her possible genetic predisposition to
HUS and hence the risk of disease recurrence. No relevant clinical history
was reported in her family.
C3 serum levels were persistently low (73 mg/dL) despite the patient
was in remission without hematological signs of the disease, while C4
levels were normal (36 mg/dL). Serum levels of factor H (415 mg/L,
normal range: 350–750 mg/L) and factor I (60.9 mg/L normal range: 38–
65 mg/L) were normal. Genetic analyses of CFH, CFI and MCP were
performed on leukocyte DNA and we found a new c.1234G > A
heterozygous missense mutation in CFI, causing the aminoacidic
substitution p.Val412Met (Figure 2A). This residue is localized in the
serine protease domain SP (Figure 2B) that is responsible for C3b
inactivation by CFI (22). The aminoacidic change Val412Met is predicted
as damaging by PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/, score
0.997) and Sift (http://sift.jcvi.org, score 0.01) softwares. The variant is
not reported in NCBI online database and was not found in any of 220
healthy controls. Homozygous deletion of CFHR3-CFHR1, previously
associated with development of anti-CFH autoantibodies and aHUS (16),
was excluded by MLPA (16).
Patient #2
The clinical history of this patient, a 23-year-old woman, started at the age
of 16 years when she presented with diarrhea, thrombocytopenia
(platelet count 33 000/mL), microangiopathic hemolytic anemia (hemoglo-
bin 6.1 gr/dL, hematocrit 17,3%), hypertension and very severe renal
failure, quickly developing ESRD (serum creatinine 21 mg/dL). Infection
by E. coli O157:H7 producing Stx1 and Stx2 was documented in stool
cultures.
At 18 years of age living-related kidney transplantation from her mother was
performed. Seven months after transplantation the patient manifested graft
dysfunction. A graft biopsy revealed intraglomerular thrombi, ischemic
alterations and arteriolar thrombosis leading to diagnosis of thrombotic
microangiopathy. Despite intensive plasma-exchange, anemia (hemoglobin
8 gr/dL), thrombocytopenia (platelet count 80 000/mL) and severe graft
dysfunction (serum creatinine 10 mg/dL) persisted and 2 months later the
patient lost the graft.
Before planning kidney transplantation, DNA samples of the patient, of her
parents and of the two siblings were sent to our center to investigate a
possible genetic predisposition to HUS and to evaluate the further risk of
disease recurrence. No relevant clinical history was reported in her family.
Both the parents and the siblings were healthy (Figure 3).
C3 and C4 serum levels were normal in the patient. Serum levels of factor H
(474 mg/L) were also normal. Genetic analyses of CFH, CFI,MCP, C3, CFB
and THBD were performed on leukocyte DNA. The patient was found to be
heterozygous for the c.286 þ 2T > G (also known as IVS2 þ 2T > G (23))
splice site mutation inMCP. This mutation has been previously described in
aHUS patients (23,24) and has been found to cause an abnormal splicing
between exons 2 and 3, resulting in either protein truncation (24) or in the
deletion of 48 aminoacids (23). The mutation was absent in 319 healthy
controls. Analysis of relatives’ DNA revealed the same mutation in the
mother and in the brother, but not in the father and the sister (Figure 3 and 4).
Homozygous deletion of CFHR3-CFHR1 was excluded by MLPA (16).
Figure 1: Renal biopsy of the native kidney from patient #1. Images show typical features of active microangiopathic process
characterized by glomerular alterations of variable severity from slight ischemic changes (A) with capillary engulfment and mesangial
proliferation (B) to infarction and mesangiolysis (C) (original magnification 400). Small arteries and arterioles showed prominent intimal
(black arrows) and subintimal proliferation leading to lumen occlusion (D) (original magnification 400). Panels E and F:
Immunohistochemistry showing C3 deposition on the endothelial layer of the glomerular tuft (E). C9 immunostaining demonstrates
diffuse terminal complement activation (C5b-9) in glomeruli with overt ischemic alterations (F). Original magnification 400, Streptavidin-
biotin-peroxidase complex method.
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Discussion
Herewe describe two unrelated patientswho debutedwith
STEC-HUS, developed ESRD soon after the onset of the
disease and experienced HUS recurrence after kidney
transplantation. This disease course is rather unusual. First,
patients with STEC-HUS usually recover from acute
episode, although on long term 25% of them develop
some degree of renal impairment (9). Second, the disease
rarely recurs in kidney transplants performed after STEC-
HUS (19). STEC-released Stx is the causative agent of
STEC-HUS, therefore a re-exposure to STEC would be
required to trigger recurrence. In addition patients with
STEC-HUS develop neutralizing anti-Stx antibodies that
persist for long-time, thus protecting from recurrences (25).
Suchsevereclinical features insteadclosely resemble those
reported in patients with aHUS and mutations in comple-
ment regulatory proteins. Consistently, genetic screening
revealed the presence of a heterozygous CFI mutation
associated with persistent low C3 levels in patient #1,
whereas a heterozygousMCP splicing mutation was found
in patient #2, who showed normal complement serum
levels, and also in her mother, who donated the kidney.
CFI encodes a plasma serine protease that regulates the
activation of complement system by inactivating C3b.
Mutations in CFI have been reported in 4–10% of aHUS
cases (1,11) but had never been previously described in
association with STEC-HUS. MCP is a transmembrane
protein that serves as cofactor for CFI to cleave C3b and
C4b deposited on host surfaces (1). MCP mutations have
been previously reported in 10–15% of aHUS patients (1),
and also in a severe fatal case of STEC-HUS (10).
Evidence is emerging that STEC triggers complement
activation, as documented by finding low C3 serum levels,
and transient plasma elevations of C3 (C3b, C3c and C3d)
and CFB (Ba, Bb) breakdown products and of sC5b9, during
the acute phase of STEC-HUS (26). In addition, Stx was
found to cause complement activation and C3 deposition
Figure 2: Sequencing electropherograms showing the c.1234G > A heterozygous mutation in CFI of patient #1. A: upper
chromatogram, forward; lower chromatogram, reverse. B: Schematic structure of CFI protein with the localization of the mutation.
Figure 3: Family pedigree of patient #2. The black circle
represents the proband carrying the heterozygous MCP mutation
c.286 þ 2T > G; healthy carriers are indicated by a black dot. WT:
Wild-type.
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on endothelial cells in vitro (27). Stx binding to endothelial
cells upregulates mRNA expression and protein levels of
cell adhesion molecules, including P-selectin (8), which has
been shown to bind C3bwith high affinity (27). Finally, mice
deficient in CFB treated with Stx and LPS exhibited less
thrombocytopenia and were protected against glomerular
abnormalities and renal function impairment as compared
withwild-typemice, providing in vivo evidence of the role of
the AP of complement in STEC-HUS (27). The evidence that
complement activation may have a pathogenic role in the
microangiopathic lesions of STEC-HUS (3) provided the
rationale for complement inhibitor therapy in three children
with severe STEC-HUS who fully recovered with Eculizu-
mab (28), an anti-C5 antibody that prevents the formation of
the anaphylotoxin C5a and of the C5b-9 lytic complex.
The above published data and present findings of intense
deposition of C3 and C5b-9 in renal biopsy of patient #1
taken at the time of STEC infection indicate that exposure to
STECmay cause complement activation and trigger severe
HUS in subjects with genetic alterations of complement
regulatory proteins. In patient #1, the kidney transplant did
not correct the CFI genetic defect, since the altered protein
is produced by the liver and persists in the circulation after
kidney transplantation (20). In such conditions, the kidney
graft was not protected from complement activation
triggered by ischemia and reperfusion injury posttransplan-
tation, alloimmune response and immunosuppressive
drugs, resulting in aHUS. Hence, the recurrence was due
to the CFI mutation and had nothing to do with the patient
having had STEC exposure in the past.
The above interpretation is consistent with published data
that in patients with aHUS carrying genetic abnormalities in
circulating regulatory proteins like CFI and CFH, the risk of
recurrence after renal transplantation is very high (11).
Eculizumab has been shown to be beneficial to treat acute
episodes of aHUS and also as prophylaxis of recurrences in
the kidney graft (29,30) in patients with aHUS and
complement gene mutations. The presence in patient #1
of a CFI mutation, along with the finding of intense
deposition of C3 and C5b-9 in renal biopsy, would provide
the rationale for a preemptive use of Eculizumab as part of a
new renal transplant plan for this patient deemed at high
risk for recurrent disease.
MCP is a transmembrane protein widely expressed in the
kidney, thus transplantation of a kidney expressing normal
MCP corrects the local genetic defect in aHUS-patient with
MCPmutations. Consequently, these patients usually have
a good graft outcomewith a low incidence of posttransplant
recurrence (20). Such observation in aHUS patients does
not fit with the finding here that patient #2 carrying anMCP
mutation experienced HUS recurrence in the graft. Such
discrepancy can be explained by the fact that patient #2
received the graft from her mother who carries the same
MCPmutation. Thus in this case the kidney graft produced
the same dysfunctional MCP protein as the native kidney
and it was not protected enough from complement
hyperactivation leading to aHUS recurrence.
In conclusion, the cases here reported indicate that
screening of HUS-associated complement genes should
be performed in all patients on dialysis following severe
forms of STEC-HUS, since they may carry complement
gene mutations and be undiagnosed cases of aHUS
precipitated by STEC infections.
A correct diagnosis is critical to predict the risk of
recurrence after transplantation and accordingly to adopt
suitable prophylactic measures. Furthermore, genetic
analysis of potential donors is mandatory before living
related transplantation.
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